Cite
HARVARD Citation
Nilsson, F. et al. (2021). The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of medical economics. pp. 447-457. [Online].